Jasper Therapeutics announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Credit Suisse Securities and William Blair & Company are acting as the active book-running managers for the proposed offering. Oppenheimer & Co. is acting as a passive book-running manager for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JSPR:
- Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
- Jasper Therapeutics Announces Proposed Public Offering of Common Stock
- Largest borrow rate increases among liquid names
- JSPR Blasts Up on New Cancer Treatment Results
- Jasper Therapeutics to present data for briquilimab at 2023 Tandem Meetings